Westwood Wealth Management Has $1.91 Million Stock Position in Eli Lilly and Company $LLY

Westwood Wealth Management reduced its stake in Eli Lilly and Company (NYSE:LLY) by 4.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,310 shares of the company’s stock after selling 100 shares during the quarter. Eli Lilly and Company comprises 0.8% of Westwood Wealth Management’s holdings, making the stock its 19th largest holding. Westwood Wealth Management’s holdings in Eli Lilly and Company were worth $1,908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. WestEnd Advisors LLC lifted its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares during the period. Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $40,000. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $43,000. Finally, O Brien Wealth Partners LLC grew its stake in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after purchasing an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on LLY. HSBC cut Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Guggenheim decreased their target price on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research note on Wednesday, August 13th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, UBS Group decreased their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $950.17.

Insider Buying and Selling

In related news, Director J Erik Fyrwald bought 1,565 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 0.1%

Shares of NYSE:LLY opened at $710.7290 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.48. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business’s 50 day simple moving average is $754.70 and its two-hundred day simple moving average is $790.90. The firm has a market cap of $672.68 billion, a P/E ratio of 46.45, a PEG ratio of 0.99 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the company earned $3.92 earnings per share. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.